MRK240927P109000
- 0.01
- -0.05-83.33%
Merck & Co Newsroom
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $142
J.P. Morgan Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $145
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $130
BofA Securities Initiates Merck & Co(MRK.US) With Buy Rating, Announces Target Price $140
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target
Merck & Co Analyst Ratings
Moderna Continues to Decline as Oppenheimer Latest to Downgrade
Moderna Extends Losses as R&D Day Updates Lead to Downgrades
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $147
After the dual-antibody drug data from Summit Therapeutics (SMMT.US) defeated the "drug king", it was listed as Citigroup's preferred stock and the target price was raised.
BMO Capital Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $150
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $147
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating
Goldman Sachs Maintains Merck & Co(MRK.US) With Buy Rating
Evercore Maintains Merck & Co(MRK.US) With Buy Rating
TD Cowen Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
TD Cowen Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $140
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Merck & Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target